

OrbusNeich Medical Group Holdings Limited 業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6929)

FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 27, 2025

I/W	'e					
of						
		 a (Note 2)			 	

being the registered holder(s) of (Note 2) shares of US\$0.0005 each in the share capital of OrbusNeich Medical Group Holdings Limited (the "Company") hereby appoint the Chairman of the annual general meeting of the Company, or (Note 3) of

as my/our proxy to attend and vote for me/us and on my/our behalf at the annual general meeting of the Company (the "**Meeting**") to be held at Multi-function Room 2–3, 2/F, Building 17W, Science Park West Avenue, Hong Kong Science Park, Hong Kong on Tuesday, May 27, 2025 at 11:00 a.m. and at any adjournment thereof for the purpose of considering and, if thought fit, passing the ordinary resolution as set out in the notice of the Meeting as indicated below or if no such indication is given, as my/our proxy thinks fit and in respect of any other of business that may properly come before the Meeting and/or at any adjournment thereof:

	ORDINARY RESOLUTIONS [#]	FOR	AGAINST			
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries, and the reports of the directors (the "Director(s)") and the independent auditor of the Company for the year ended December 31, 2024.					
2.	(a) To re-elect Mr. David CHIEN as an executive Director.					
	(b) To re-elect Ms. Kwai Ching Denise LAU as an executive Director.					
	(c) To re-elect Mr. Wing Sing CHEN as an executive Director.					
	(d) To authorize the board of directors (the " Board ") of the Company to fix the Director's remuneration.					
3.	To re-appoint PricewaterhouseCoopers as the auditor of the Company and to authorize the Board to fix its remuneration.					
4.	To approve and declare the payment of a final dividend of HK10 cents per share out of the share premium account of the Company for the year ended December 31, 2024.					
5.	(a) To grant a general mandate to the Directors to allot, issue and deal with additional shares of the Company (including any sale or transfer of treasury shares) not exceeding 20% of the aggregate number of the issued shares (excluding treasury shares, if any) as of the date of passing of this resolution.					
	(b) To grant a general mandate to the Directors to repurchase the shares of the Company not exceeding 10% of the aggregate number of issued shares (excluding treasury shares, if any) of the Company as of the date of passing of this resolution.					

The description of each resolution herein is by way of summary only. Full text of the relevant resolutions is set out in the notice dated April 17, 2025 convening the Meeting.

(Note 5) Dated this day of 2025 Signature Notes:

1. 2.

3. 4

Full name(s) and address(es) must be inserted in **BLOCK CAPITALS**. The name of all joint holders should be stated. Please insert the number of shares registered in your name(s) to which the proxy relates. If no number is inserted, this form of proxy will be deemed to relate to all the shares of the Company registered in your name(s). If any proxy other than the Chairman is preferred, please strike out "the Chairman of the annual general meeting of the Company, or" and insert the name and address of the proxy desired in the space provided. ANY ALTERATION MADE TO THIS FORM OF PROXY MUST BE INITIALLED BY THE PERSON(S) WHO SIGN(S) IT. IMPORTANT: IF YOU WISH TO VOTE FOR THE RESOLUTION, TICK THE BOX MARKED "FOR". IF YOU WISH TO VOTE AGAINST THE RESOLUTION, TICK THE BOX MARKED "AGAINST". Failure to tick either box will entitle your proxy to cast your ote or abstain at his/her discretion. Your proxy will also be entitled to vote or abstain at his/her discretion on any resolution properly put to the Meeting and/or at any adjournment thereof other than those referred to in the notice convening the Meeting and/or at any adjournment thereof other than those referred to in the notice convening the Meeting and/or at any adjournment thereof other than those referred to in the notice convening the Meeting and/or at any adjournment thereof other than those referred to in the notice convening the Meeting and/or at any adjournment thereof other than those referred to in the notice convening the Meeting and/or at any adjournment thereof other than those referred to in the notice convening the Meeting and Me the Meeting.

PERSONAL INFORMATION COLLECTION STATEMENT

Your supply of your and your proxy's (or proxies') name(s) and address(es) is on a voluntary basis for the purpose of processing your request for the appointment of a proxy (or proxies) and your your ginstructions for the AGM of the Company (the "**Purposes**"). We may transfer your and your proxy's (or proxies') name(s) and address(es) to our agent, contractor, or third party service provider who provides administrative, computer and other services to us for use in connection with the Purposes and to such parties who are authorized by law to request the information or are otherwise relevant for the Purposes and need to receive the information. Your and your proxy's (or proxies') name(s) and address(es) will be retained for such period as may be necessary to fulfil the Purposes. Request for access to and/or correction of the relevant personal data can be made in accordance with the provisions of the Personal Data (Privacy) Ordinance and any such request should be in writing by mail to the Company.

This form of proxy shall be in writing under the hand of the appointor or of his/her attorney duly authorized in writing or, if the appointor is a corporation, either under its seal or under the hand of an officer, attorney or other person authorized to sign the same. In the case of this form of proxy purporting to be signed on behalf of a corporation by an officer thereof it shall be assumed, unless the contrary appears, that such officer was duly authorized to sign this form on behalf of the corporation without further 5. evidence of the fact.

Any member entitled to attend and vote at the Meeting is entitled to appoint another person as his/her proxy to attend and vote instead of him/her. A member holding two or more shares may appoint more than one proxy. A member may appoint a proxy in respect of part only of his/her holding of shares in the Company. A proxy need not be a member of the Company. 6

member of the Company. This form of proxy and (if required by the board of directors of the Company) the power of attorney or other authority (if any) under which it is signed, or a certified copy of such power or authority, must be deposited at the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for the meeting or the adjourned meeting thereof at which the person named in this form proposes to vote or, in the case of a poll taken subsequently to the date of the Meeting or adjourned meeting, not less than 48 hours before the time appointed for the taking of the poll and in default this form of proxy shall not be treated as valid. Delivery of this form of proxy shall not preclude a member from attending and voting in person at the Meeting and in such event, this form of proxy shall be deemed to be revoked. Where there are joint holders of any share any one of such joint holders may vote, either in person or by proxy, in respect of such share as if he were solely entitled thereto, but if more than one of such ionit holders he present at the Meeting the varie of the senior who reders a view were the view proxy. 7.

^{8.}

^{9.} if more than one of such joint holders be present at the Meeting the vote of the senior who tenders an vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and for this purpose seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the joint holding. The notice of the Meeting is set out in the Company's circular dated April 17, 2025.

^{10.}